CD47 and CD68 expression in breast cancer is associated with tumor-infiltrating lymphocytes, blood vessel invasion, detection mode, and prognosis.
CD47
CD68 macrophages
breast cancer
lymphatic and blood vessel invasion
mammography screening
prognosis
tumor-infiltrating lymphocytes (TILs)
Journal
The journal of pathology. Clinical research
ISSN: 2056-4538
Titre abrégé: J Pathol Clin Res
Pays: England
ID NLM: 101658534
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
16
12
2022
received:
22
06
2022
accepted:
23
12
2022
medline:
6
4
2023
pubmed:
5
1
2023
entrez:
4
1
2023
Statut:
ppublish
Résumé
CD47 expressed on tumor cells binds to signal regulatory protein alpha on macrophages, initiating inhibition of phagocytosis. We investigated the relationships between tumor expression of CD47 and CD68 macrophage content, subsets of tumor-infiltrating lymphocytes (TILs), and vascular invasion in breast cancer. A population-based series of 282 cases (200 screen detected and 82 interval patients) from the Norwegian Breast Cancer Screening Program was examined. Immunohistochemical staining for CD47 and CD68 was evaluated on tissue microarray (TMA) slides. For CD47 evaluation, a staining index was used. CD68 tumor-associated macrophages were counted and dichotomized. TIL subsets (CD45, CD3, CD4, CD8, and FOXP3) were counted and dichotomized using immunohistochemistry on TMA slides. Vascular invasion (both lymphatic and blood vessel) was determined on whole tissue slides. High CD47 tumor cell expression or high counts of CD68 macrophages were significantly associated with elevated levels of all TIL subsets (p < 0.02), CD163 macrophages (p < 0.001), blood vessel invasion (CD31 positive) (p < 0.01), and high tumor cell Ki67 (p < 0.004). High CD47 expression was associated with ER negativity (p < 0.001), HER2 positive status (p = 0.03), and interval-detected tumors (p = 0.03). Combined high expression of CD47-CD68 was associated with a shorter recurrence-free survival (RFS) by multivariate analysis (hazard ratio [HR]: 2.37, p = 0.018), adjusting for tumor diameter, histologic grade, lymph node status, and molecular subtype. Patients with luminal A tumors showed a shorter RFS for CD47-CD68 high cases by multivariate assessment (HR: 5.73, p = 0.004). This study demonstrates an association of concurrent high CD47 tumor cell expression and high CD68 macrophage counts with various TIL subsets, blood vessel invasion (CD31 positive), other aggressive tumor features, and interval-presenting breast cancer. Our findings suggest a link between CD47, tumor immune response, and blood vessel invasion (CD31 positive). Combined high expression of CD47-CD68 was an independent prognostic factor associated with poor prognosis in all cases, as well as in the luminal A category.
Identifiants
pubmed: 36598153
doi: 10.1002/cjp2.309
pmc: PMC10073931
doi:
Substances chimiques
CD47 Antigen
0
CD47 protein, human
0
CD68 antigen, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
151-164Informations de copyright
© 2022 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd.
Références
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Cancer Cell Int. 2019 Sep 11;19:238
pubmed: 31528120
Oncotarget. 2014 Sep 30;5(18):8147-60
pubmed: 25230070
Br J Cancer. 2017 Jul 25;117(3):385-397
pubmed: 28632731
Front Immunol. 2020 Jan 28;11:18
pubmed: 32082311
Cancer Lett. 2017 Feb 28;387:61-68
pubmed: 26845449
J Neurosci Res. 2009 Aug 15;87(11):2571-7
pubmed: 19360900
Front Oncol. 2021 Mar 11;11:610303
pubmed: 33777750
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Oncotarget. 2017 Jun 13;8(24):39021-39032
pubmed: 28380460
Biomaterials. 2021 Feb;269:120667
pubmed: 33450585
Cell Stem Cell. 2014 Mar 6;14(3):306-21
pubmed: 24607405
Transl Oncol. 2020 Dec;13(12):100862
pubmed: 32920329
Trends Immunol. 2010 Jun;31(6):212-9
pubmed: 20452821
Expert Opin Biol Ther. 2010 Nov;10(11):1573-86
pubmed: 20955112
Cell Cycle. 2011 Jan 1;10(1):10-2
pubmed: 21191182
J Clin Oncol. 2014 Sep 20;32(27):2959-66
pubmed: 25071121
Curr Opin Immunol. 2009 Feb;21(1):47-52
pubmed: 19223164
J Pathol Clin Res. 2021 Sep;7(5):517-527
pubmed: 34076969
Br J Pharmacol. 2012 Dec;167(7):1415-30
pubmed: 22774848
Oncotarget. 2016 Mar 1;7(9):10133-52
pubmed: 26840086
Sci Rep. 2016 Jul 14;6:29719
pubmed: 27411490
Onco Targets Ther. 2019 Nov 04;12:9105-9114
pubmed: 31806995
J Biol Chem. 2006 Sep 8;281(36):26069-80
pubmed: 16835222
Oncol Lett. 2019 Feb;17(2):2177-2186
pubmed: 30675282
Cell Adh Migr. 2012 May-Jun;6(3):193-202
pubmed: 22568980
Curr Opin Immunol. 2012 Apr;24(2):225-32
pubmed: 22310103
Hepatology. 2014 Jul;60(1):179-91
pubmed: 24523067
Immunol Rev. 2017 Mar;276(1):145-164
pubmed: 28258703
Br J Haematol. 2014 Jan;164(2):304-7
pubmed: 24164421
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6656-61
pubmed: 22451919
Int J Cancer. 1997 Oct 21;74(5):535-9
pubmed: 9355977
J Immunol. 2012 Sep 1;189(5):2553-62
pubmed: 22815286
Curr Opin Oncol. 2018 Sep;30(5):332-337
pubmed: 29994903
J Immunol. 2014 Oct 15;193(8):3914-24
pubmed: 25200950
Am J Transl Res. 2019 Aug 15;11(8):5039-5053
pubmed: 31497220
Nat Commun. 2020 Sep 14;11(1):4591
pubmed: 32929084
Breast Cancer Res. 2021 Feb 18;23(1):27
pubmed: 33602289
Oncoimmunology. 2018 Mar 13;7(4):e1397248
pubmed: 29632717
J Thorac Dis. 2017 Feb;9(2):E168-E174
pubmed: 28275508
Crit Rev Oncol Hematol. 2020 Aug;152:103014
pubmed: 32535479
Histol Histopathol. 2018 Feb;33(2):133-145
pubmed: 28681373
BMC Cancer. 2021 Mar 25;21(1):320
pubmed: 33765961
J Hematol Oncol. 2017 Jan 11;10(1):12
pubmed: 28077173
Oncol Lett. 2019 Sep;18(3):3249-3255
pubmed: 31452802
Breast. 2013 Aug;22 Suppl 2:S3-7
pubmed: 24074788
Clin Cancer Res. 2010 Sep 15;16(18):4625-35
pubmed: 20705613
J Hematol Oncol. 2019 Nov 27;12(1):124
pubmed: 31771616
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Int J Oncol. 2013 Jul;43(1):5-12
pubmed: 23673510
Front Oncol. 2020 Feb 25;10:188
pubmed: 32161718
J Immunother Cancer. 2019 Dec 11;7(1):346
pubmed: 31829270
Int J Mol Sci. 2021 Mar 07;22(5):
pubmed: 33799989
Cent European J Urol. 2017;70(4):349-355
pubmed: 29410884
Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1239-E1248
pubmed: 29367423
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14016-21
pubmed: 19666525
Pathol Res Pract. 2019 Feb;215(2):265-271
pubmed: 30466764
Hum Pathol. 2017 Nov;69:72-80
pubmed: 28923419
J Clin Pathol. 2017 Apr;70(4):313-319
pubmed: 27612505
Clin Transl Oncol. 2016 Mar;18(3):251-8
pubmed: 26264497
Adv Exp Med Biol. 2018;1092:69-90
pubmed: 30368749
Nat Med. 2015 Oct;21(10):1122-3
pubmed: 26444633
Cancer Sci. 2018 Aug;109(8):2349-2357
pubmed: 29873856
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7
pubmed: 22451913
N Engl J Med. 2009 Feb 19;360(8):790-800
pubmed: 19228622
Clin Cancer Res. 2015 Aug 15;21(16):3597-601
pubmed: 26116271
Cell. 2009 Jul 23;138(2):271-85
pubmed: 19632178
JAMA Oncol. 2017 Nov 09;3(11):e172085
pubmed: 28750133
Oncotarget. 2017 Apr 4;8(14):22406-22413
pubmed: 27283989
J Immunol. 2008 Feb 15;180(4):2011-7
pubmed: 18250403
J Pathol. 2000 Mar;190(4):430-6
pubmed: 10699991